相关临床试验
12
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
12
100.0%
暂无批准数据
- CD70 overexpression at diagnosis predicts relapse and shorter progression-free survival in follicular lymphoma patients with over 11 years of follow-up. - A novel dual CD19-CD70 CAR-T therapy, combining ARI-0001 with a CD27-based anti-CD70 CAR, demonstrated enhanced antitumor activity in patient-derived models. - The dual-target strategy achieved superior disease control compared to conventional CD19-directed CAR-T in preclinical follicular lymphoma models. - Researchers plan to complete safety studies and prepare regulatory documentation to enable a clinical trial application for this next-generation CAR-T therapy.
- Researchers have developed a functional classification system for CTNNB1 mutations that can predict immunotherapy response in hepatocellular carcinoma patients. - The study analyzed 342 genetic variants and classified mutations as "strong" or "weak" based on their activation of the WNT/β-catenin pathway using CRISPR-based genome editing. - Strong mutations create immunosuppressive environments resistant to therapy, while weak mutations allow immune cell infiltration and better treatment response. - The classification was validated in 124 patient samples and has implications for precision medicine approaches in liver cancer and other solid tumors.
- REVEAL GENOMICS presented seven studies at SABCS 2025 analyzing over 1,300 tumor samples, showcasing major advances in precision oncology for breast cancer patients. - The company's newly developed HER2DX CNS Progression Score demonstrated strong risk stratification ability, with 3-year CNS progression rates of 39.2% in high-risk versus 4.3% in low-risk groups. - Multiple validation studies confirmed the superior predictive performance of HER2DX genomic scores over traditional biomarkers like tumor-infiltrating lymphocytes across different breast cancer subtypes. - The DEFINITIVE trial showed 94.3% success rate for HER2DX testing with 7-day median turnaround time, supporting real-time genomic testing integration in clinical practice.
- The European Medicines Agency has designated allopurinol as the first orphan drug for Marfan syndrome, a rare connective tissue disease affecting approximately 7 in 100,000 people in the European Union. - Researchers from the University of Barcelona, IDIBAPS, and CIBERER have demonstrated allopurinol's potential to halt and prevent aortic aneurysms in animal models, with international clinical trials in patients planned for the future. - This repurposing of allopurinol, currently used for gout treatment, represents a significant advancement for Marfan syndrome patients who currently have no curative options beyond limited palliative treatments and high-risk surgical interventions.
